FULC — Fulcrum Therapeutics Share Price
0.000.00%
Last trade - 00:00- $303.36m
- $76.76m
- $80.00m
- 78
- 19
- 72
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.33 | ||
| Price to Tang. Book | 1.33 | ||
| Price to Free Cashflow | 40.13 | ||
| Price to Sales | 3.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5.31% | ||
| Return on Equity | -0.23% | ||
| Operating Margin | -15.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8.82 | 19.16 | 6.34 | 2.81 | 80 | n/a | 20.34 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
Directors
- Kate Haviland CHM (45)
- Bryan Stuart PRE (44)
- Esther Rajavelu CFO (43)
- Judith Dunn CEX (59)
- Christopher Moxham CSO (53)
- Curtis Oltmans GCN (57)
- Mel Hayes OTH
- Robert Gould DRC (66)
- Mark Levin DRC (70)
- Sonja Banks IND
- James Collins IND (55)
- Katina Dorton IND (63)
- Alan Ezekowitz IND (67)
- James Geraghty IND (67)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- August 18th, 2015
- Public Since
- July 18th, 2019
- No. of Shareholders
- 11
- No. of Employees
- 45
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 53,979,306
- Address
- 26 Landsdowne Street, CAMBRIDGE, 02139
- Web
- https://www.fulcrumtx.com/
- Phone
- +1 6176518851
- Contact
- Chris Calabrese
- Auditors
- Ernst & Young LLP
Upcoming Events for FULC
Q2 2025 Fulcrum Therapeutics Inc Earnings Release
Similar to FULC
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Fulcrum Therapeutics share price?
As of Today at 20:44 UTC, shares in Fulcrum Therapeutics are trading at $5.62. This share price information is delayed by 15 minutes.
How has the Fulcrum Therapeutics share price performed this year?
Shares in Fulcrum Therapeutics last closed at $5.62 and the price had moved by -26.54% over the past 365 days. In terms of relative price strength the Fulcrum Therapeutics share price has underperformed the S&P500 Index by -33.76% over the past year.
What are the analyst and broker recommendations for Fulcrum Therapeutics?
The overall consensus recommendation for Fulcrum Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Fulcrum Therapeutics dividend yield?
Fulcrum Therapeutics does not currently pay a dividend.
Does Fulcrum Therapeutics pay a dividend?
Fulcrum Therapeutics does not currently pay a dividend.
When does Fulcrum Therapeutics next pay dividends?
Fulcrum Therapeutics does not currently pay a dividend.
How do I buy Fulcrum Therapeutics shares?
To buy shares in Fulcrum Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Fulcrum Therapeutics?
As of the previous close price of $5.62, shares in Fulcrum Therapeutics had a market capitalisation of $303.36m.
Where are Fulcrum Therapeutics shares listed?
Here are the trading details for Fulcrum Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: FULC
What kind of share is Fulcrum Therapeutics?
Based on an overall assessment of its quality, value and momentum Fulcrum Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Fulcrum Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Fulcrum Therapeutics is $5.33. That is 5.16% below the last closing price of $5.62.
Analysts covering Fulcrum Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.20 for the next financial year.
Find out moreWhat is the trend in the Fulcrum Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fulcrum Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +75.88%.
As of the last closing price of $5.62, shares in Fulcrum Therapeutics were trading +20.96% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Fulcrum Therapeutics PE Ratio?
The Fulcrum Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.62.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Fulcrum Therapeutics?
Fulcrum Therapeutics' management team is headed by:
- Kate Haviland - CHM
- Bryan Stuart - PRE
- Esther Rajavelu - CFO
- Judith Dunn - CEX
- Christopher Moxham - CSO
- Curtis Oltmans - GCN
- Mel Hayes - OTH
- Robert Gould - DRC
- Mark Levin - DRC
- Sonja Banks - IND
- James Collins - IND
- Katina Dorton - IND
- Alan Ezekowitz - IND
- James Geraghty - IND